Brief: Enlivex receives israeli ministry of health approval for the initiation of a Phase I/Ii Trial Evaluating Allocetra™
17/08/2022 13:14
Aug 17 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES ISRAELI MINISTRY OF HEALTH APPROVAL FOR
THE
INITIATION OF A PHASE I/II TRIAL EVALUATING ALLOCETRA™ ALONE AND
IN COMBINATION WITH A PD1 CHECKPOINT INHIBITOR IN PATIENTS WITH
ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNX38gtzf
Further company coverage: ENLV.TA
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment